Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms

NCT07272512 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07272512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07272512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
November 11, 2025
Completion date
November 29, 2028
Enrollment
350 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine neoplasms, neuroendocrine tumors